- OnQ™ Prostate
Optimizing prostate MRI for advanced clinical insights
OnQ Prostate is an FDA-cleared software solution using Restriction Spectrum Imaging (RSI), a patented diffusion MRI method that has been shown to improve detection, in vivo characterization, and localization of clinically significant cancer.
Improved accuracy for quality reads
Through clear, easy-to-interpret images OnQ™ Prostate empowers collaborative decision-making and enhances targeting for biopsy and therapy. Elevating clinical workflows that use MRI for prostate cancer detection, monitoring, and treatment, it helps bridge the gaps between radiologists and referring physicians.
Benefits
Detection and prediction
Of clinically significant cancer
Improved tumor conspicuity
And differentiation from non-tumor
Stronger histopathology correlation
Based on Gleason Score
OnQ™ Prostate outputs
OnQ™ Prostate achieves improved PI-RADS accuracy and inter-reader agreement.
Restricted Signal Map
Shows areas of restricted diffusion with increased conspicuity compared to acquired and computed high b-value DWI
Color Fusion Map
Automatically fuses the restricted signal with the T2 for anatomic localization.
